《与低磷脂含量磷虾油相比,补充高磷脂含量磷虾油增加红细胞中EPA和DHA的总量》Ramprasath VR, Eyal I et al.Lipids Health Dis. 2015 Nov 4;14:142. doi: 10.1186/s12944-015-0142-y.|中冠生物科技(珲春)有限公司 

首页>研究进展

《与低磷脂含量磷虾油相比,补充高磷脂含量磷虾油增加红细胞中EPA和DHA的总量》

Ramprasath VR, Eyal I et al.Lipids Health Dis. 2015 Nov 4;14:142. doi: 10.1186/s12944-015-0142-y.

摘要:
背景
磷虾油的生物利用度被认为比鱼油高,这是因为磷虾油中的EPA和DHA与磷脂(PL)相结合。因此,磷虾油中的磷脂可能在n-3 PUFA结合到红细胞中发挥重要作用,赋予其降低心血管疾病(CVD)风险的特性。本试验的目的是测试健康志愿者服用不同磷脂含量的磷虾油对EPA和DHA生物利用度的影响,以血浆和红细胞中n-3 多不饱和脂肪酸的增加速度为评价指标。
方法与设计:
在一项半随机交叉单盲设计研究中,20名健康受试者分别服用1.5克/天低磷脂含量的磷虾油(LPL)、3g/天高磷脂含量的磷虾油(HPL)或3克/天安慰剂玉米油,每次4周,间隔8周洗脱期。低磷脂含量磷虾油(LPL)组和高磷脂含量磷虾油组(HPL)都每天提供600毫克的n-3不饱和脂肪酸以及600毫克/天和1200毫克/天的磷脂。
结果:
补充低磷脂含量和高磷脂含量的磷虾油,血浆中的EPA、DPA、DHA、总n-3 脂肪酸、n-6:n-3比率和EPA+DHA浓度的变化是相似的。与对照组相比,两种形式磷虾油的摄入增加了血红细胞中EPA的水平(p<0.001),同时降低了n-6 脂肪酸含量(LPL: p < 0.001: HPL: p = 0.007)。与低磷脂含量的磷虾油组相比,高磷脂含量磷虾油组提高了红细胞中EPA、DPA、总n-3 脂肪酸的浓度(p<0.001)。此外,与对照组相比,低磷脂含量磷虾油组并未改变血红蛋白中omega-3指数, n-6:n-3比率或EPA和DHA之和,而与对照组、低磷脂含量磷虾油组比较,高磷脂含量磷虾油降低了n-6:n-3比率(p< 0.001)。高磷脂含量磷虾油改善了(p<0.005)血浆总胆固醇和低密度脂蛋白胆固醇浓度,而低磷脂含量磷虾油不会改变总胆固醇和低密度脂蛋白胆固醇浓度。
结论:
结果表明,与低磷脂水平的磷虾油相比,高磷脂水平的磷虾油可以提高n-3脂肪酸的生物利用度。
临床注册号
Clinicaltrials.gov# NCT01323036.

Abstract:
Background:
Bioavailability of krill oil has been suggested to be higher than fish oil as much of the EPA and DHA in krill oil are bound to phospholipids (PL). Hence, PL content in krill oil might play an important role in incorporation of n-3 PUFA into the RBC, conferring properties that render it effective in reducing cardiovascular disease (CVD) risk. The objective of the present trial was to test the effect of different amounts of PL in krill oil on the bioavailability of EPA and DHA, assessed as the rate of increase of n-3 PUFA in plasma and RBC, in healthy volunteers.
Methods And Design: 
In a semi randomized crossover single blind design study, 20 healthy participants consumed various oils consisting of 1.5 g/day of low PL krill oil (LPL), 3 g/day of high PL krill oil (HPL) or 3 g/day of a placebo, corn oil, for 4 weeks each separated by 8 week washout periods. Both LPL and HPL delivered 600 mg of total n-3 PUFA/day along with 600 and 1200 mg/day of PL, respectively.
Results:
Changes in plasma EPA, DPA, DHA, total n-3 PUFA, n-6:n-3 ratio and EPA + DHA concentrations between LPL and HPL krill oil supplementations were observed to be similar. Intake of both forms of krill oils increased the RBC level of EPA (p < 0.001) along with reduced n-6 PUFA (LPL: p < 0.001: HPL: p = 0.007) compared to control. HPL consumption increased (p < 0.001) RBC concentrations of EPA, DPA, total and n-3 PUFA compared with LPL. Furthermore, although LPL did not alter RBC n-6:n-3 ratio or the sum of EPA and DHA compared to control, HPL intake decreased (p < 0.001) n-6:n-3 ratio relative to control with elevated (p < 0.001) sum of EPA and DHA compared to control as well as to LPL krill oil consumption. HPL krill oil intake elevated (p < 0.005) plasma total and LDL cholesterol concentrations compared to control, while LPL krill oil did not alter total and LDL cholesterol, relative to control.
Conclusions:
The results indicate that krill oil with higher PL levels could lead to enhanced bioavailability of n-3 PUFA compared to krill oil with lower PL levels.
TRIAL REGISTRATION: 
Clinicaltrials.gov# NCT01323036.